WallStSmart
UNCY

Unicycive Therapeutics Inc

NASDAQ: UNCY · HEALTHCARE · BIOTECHNOLOGY

$7.95
-6.86% today

Updated 2026-06-05

Market cap
$156.96M
P/E ratio
P/S ratio
23.75x
EPS (TTM)
$-2.25
Dividend yield
52W range
$4 – $9
Volume
1.5M

Unicycive Therapeutics Inc (UNCY) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$0.00$0.00$951000.00$675000.00$0.00$0.00
Revenue growth (YoY)-29.0%-100.0%
Cost of revenue$1000.00$7000.00$284000.00$428000.00$572000.00
Gross profit$-1000.00$951000.00$675000.00$-428000.00$-572000.00
Gross margin100.0%100.0%
R&D$344000.00$795000.00$1.01M$6.08M$12.44M$12.90M$20.01M$9.12M
SG&A$608000.00$1.17M$1.00M$2.90M$6.57M$8.55M$12.10M$20.40M
Operating income$-952000.00$-1.96M$-2.02M$-8.98M$-18.05M$-20.77M$-32.12M$-29.52M
Operating margin-1898.2%-3077.6%
EBITDA$-2.03M$-2.02M$-8.96M$-17.89M$-30.18M$-36.23M$-25.91M
EBITDA margin-1881.3%-4470.8%
EBIT$-952000.00$-1.96M$-2.02M$-8.98M$-18.05M$-30.46M$-36.66M$-26.48M
Interest expense$0.00$139000.00$244000.00$628000.00$6000.00$82000.00$71000.00$71000.00
Income tax$-952000.00$139000.00$244000.00$615000.00$6000.00$116105.00$-1.09M
Effective tax rate45.9%-6.4%-10.8%-6.1%-0.0%-0.4%2.9%0.0%
Net income$-1.12M$-2.30M$-2.51M$-10.63M$-18.06M$-30.54M$-36.73M$-26.55M
Net income growth (YoY)-105.7%-8.9%-323.9%-69.9%-69.1%-20.2%+27.7%
Profit margin-1899.5%-4525.0%

Frequently asked questions

How much free cash flow does UNCY generate?

UNCY produced $-31.34M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is UNCY's balance sheet healthy?

UNCY holds $29.20M in cash and equivalents against — in long-term debt, on $30.20M of shareholder equity. That debt is best read against the cash flow the business throws off each year.